Omega Therapeutics IncNASDAQ:OMGA
- LAST PRICE1.9800
- TODAY'S CHANGE (%)0.0200 (1.0204%)
- Bid / Lots1.9900/ 5
- Ask / Lots2.0500/ 2
- Open / Previous Close1.9900 / 1.9600
- Day Range
- 52 Week Range
- Volume388,707
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OMGA |
|---|---|---|
| 09:32 ET | 6419 | 2.04 |
| 09:34 ET | 1812 | 2.015 |
| 09:36 ET | 200 | 2.015 |
| 09:38 ET | 610 | 2 |
| 09:39 ET | 400 | 2.0201 |
| 09:41 ET | 559 | 2.02 |
| 09:43 ET | 3295 | 2.02 |
| 09:45 ET | 200 | 2.01 |
| 09:48 ET | 157 | 2.01 |
| 09:50 ET | 120 | 2.0027 |
| 09:52 ET | 5289 | 2.035 |
| 09:54 ET | 5100 | 2.04 |
| 09:57 ET | 305 | 2.045 |
| 09:59 ET | 188 | 2.05 |
| 10:08 ET | 9477 | 2.02 |
| 10:10 ET | 5600 | 2.01 |
| 10:12 ET | 200 | 2 |
| 10:15 ET | 100 | 2 |
| 10:17 ET | 400 | 2.01 |
| 10:19 ET | 600 | 2.0152 |
| 10:24 ET | 1921 | 2.05 |
| 10:26 ET | 110 | 2.05 |
| 10:32 ET | 1401 | 2.05 |
| 10:33 ET | 4025 | 2.0534 |
| 10:39 ET | 5252 | 2.07 |
| 10:42 ET | 351 | 2.08 |
| 10:44 ET | 300 | 2.08 |
| 10:48 ET | 900 | 2.05 |
| 10:50 ET | 366 | 2.06 |
| 10:51 ET | 200 | 2.05 |
| 10:53 ET | 100 | 2.05 |
| 10:55 ET | 100 | 2.05 |
| 10:57 ET | 100 | 2.05 |
| 11:06 ET | 1136 | 2.04 |
| 11:08 ET | 700 | 2.04 |
| 11:13 ET | 200 | 2.03 |
| 11:22 ET | 3215 | 2.035 |
| 11:24 ET | 200 | 2.03 |
| 11:27 ET | 200 | 2.01 |
| 11:29 ET | 100 | 2.03 |
| 11:31 ET | 777 | 2.03 |
| 11:33 ET | 200 | 2.02 |
| 11:36 ET | 530 | 2.02 |
| 11:38 ET | 3887 | 1.99 |
| 11:40 ET | 100 | 1.99 |
| 11:42 ET | 100 | 1.99 |
| 11:45 ET | 1300 | 1.99 |
| 11:47 ET | 100 | 1.99 |
| 11:51 ET | 200 | 1.99 |
| 11:54 ET | 100 | 1.99 |
| 11:58 ET | 1192 | 2 |
| 12:02 ET | 100 | 2 |
| 12:03 ET | 100 | 2.01 |
| 12:05 ET | 100 | 2 |
| 12:14 ET | 2400 | 2 |
| 12:16 ET | 100 | 1.99 |
| 12:18 ET | 100 | 1.99 |
| 12:23 ET | 100 | 1.99 |
| 12:25 ET | 488 | 1.99 |
| 12:27 ET | 200 | 1.99 |
| 12:30 ET | 100 | 2.0077 |
| 12:34 ET | 100 | 2.0082 |
| 12:38 ET | 200 | 1.99 |
| 12:43 ET | 2397 | 1.99 |
| 12:48 ET | 300 | 1.995 |
| 12:52 ET | 202 | 1.99 |
| 12:56 ET | 1560 | 1.99 |
| 12:57 ET | 600 | 1.985 |
| 12:59 ET | 695 | 1.985 |
| 01:01 ET | 815 | 1.99 |
| 01:03 ET | 1281 | 1.99 |
| 01:08 ET | 1002 | 1.9994 |
| 01:14 ET | 800 | 2.01 |
| 01:15 ET | 100 | 2 |
| 01:26 ET | 9600 | 2.02 |
| 01:28 ET | 100 | 2.02 |
| 01:30 ET | 100 | 2.01 |
| 01:33 ET | 2700 | 2.02 |
| 01:37 ET | 5100 | 2.02 |
| 01:39 ET | 1650 | 2.02 |
| 01:42 ET | 100 | 2.01 |
| 01:44 ET | 100 | 2.01 |
| 01:46 ET | 400 | 2.01 |
| 01:48 ET | 4868 | 2.03 |
| 01:50 ET | 200 | 2.03 |
| 01:51 ET | 300 | 2.03 |
| 02:00 ET | 100 | 2.02 |
| 02:02 ET | 300 | 2.04 |
| 02:04 ET | 100 | 2.02 |
| 02:06 ET | 300 | 2.02 |
| 02:08 ET | 384 | 2.02 |
| 02:09 ET | 200 | 2.02 |
| 02:11 ET | 100 | 2.025 |
| 02:13 ET | 830 | 2.02 |
| 02:15 ET | 3716 | 2.02 |
| 02:22 ET | 1000 | 2.02 |
| 02:24 ET | 100 | 2.02 |
| 02:26 ET | 400 | 2.015 |
| 02:27 ET | 1100 | 2.01 |
| 02:31 ET | 3674 | 2 |
| 02:33 ET | 500 | 1.99 |
| 02:36 ET | 100 | 1.99 |
| 02:38 ET | 1800 | 2.01 |
| 02:51 ET | 100 | 2.005 |
| 02:54 ET | 100 | 2 |
| 02:58 ET | 300 | 2 |
| 03:00 ET | 100 | 2.005 |
| 03:02 ET | 1493 | 2 |
| 03:03 ET | 200 | 2 |
| 03:09 ET | 100 | 2 |
| 03:14 ET | 200 | 2.005 |
| 03:16 ET | 625 | 2 |
| 03:20 ET | 2195 | 2.015 |
| 03:23 ET | 300 | 2.02 |
| 03:25 ET | 2375 | 2.0208 |
| 03:27 ET | 2200 | 2.0201 |
| 03:30 ET | 300 | 2.02 |
| 03:32 ET | 1500 | 2.01 |
| 03:34 ET | 7462 | 2.015 |
| 03:39 ET | 300 | 2.01 |
| 03:41 ET | 3172 | 2 |
| 03:43 ET | 10751 | 1.99 |
| 03:45 ET | 2100 | 1.99 |
| 03:48 ET | 3068 | 1.99 |
| 03:50 ET | 800 | 1.99 |
| 03:52 ET | 4800 | 1.99 |
| 03:54 ET | 12887 | 1.995 |
| 03:56 ET | 900 | 1.98 |
| 03:57 ET | 900 | 1.98 |
| 03:59 ET | 5554 | 1.98 |
May 30, 2024
Omega Therapeutics To Participate In Two Upcoming Investor Conferences, from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
Press Release: Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow JonesOmega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow Jones
May 13, 2024
DJ Omega Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co., from 6:46AM ET on Monday May 13, 2024 by Dow Jones
6:46AM ET on Monday May 13, 2024 by Dow Jones
May 8, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Omega Therapeutics Inc | 109.2M | -1.2x | --- |
Beyondspring Inc | 102.6M | -4.9x | --- |
PDS Biotechnology Corp | 109.3M | -2.2x | --- |
Armata Pharmaceuticals Inc | 98.3M | -1.2x | --- |
DiaMedica Therapeutics Inc | 110.1M | -5.2x | --- |
Coya Therapeutics Inc | 111.4M | -8.6x | --- |
Company Information
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
Contact Information
- Headquarters
- 140 First Street, Suite 501CAMBRIDGE, MA, United States 02141
- Phone
- 617-949-4360
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Christian Schade
- President, Chief Executive Officer, Director
- Mahesh Karande
- Principal Financial Officer, Senior Vice President - Finance, Principal Accounting Officer
- Barbara Chan
- Chief Financial Officer
- Joshua Reed
- Chief Human Resource Officer
- Kevin McManus
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $109.2M |
|---|---|
Revenue (TTM) | $4.9M |
Shares Outstanding | 55.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.67 |
Book Value | $1.05 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 22.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,921.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
